Background Most targeted anticancer therapies, as well as cytotoxic and radiation therapies,
are encumbered by the development of secondary resistance by cancer cells. Resistance is …

Abstract Learning Objectives After completing this course, the reader will be able to: Identify
the rationale for the development of dual ErbB receptor inhibitors. Describe safety data from …

Radiation recall is an acute inflammatory reaction confined to previously irradiated areas
that can be triggered when chemotherapy agents are administered after radiotherapy. It …

Background Patients with metastatic urothelial carcinoma have few treatment options after
failure of platinum-based chemotherapy. In this trial, we assessed treatment with …

Background Resistance to endocrine therapy in breast cancer is associated with activation
of the mammalian target of rapamycin (mTOR) intracellular signaling pathway. In early …

Background Resistance to therapy with BRAF kinase inhibitors is associated with
reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this …

There have been no major advances for the treatment of metastatic urothelial bladder
cancer (UBC) in the last 30 years. Chemotherapy is still the standard of care. Patient …

Background The inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6) could potentially
overcome or delay resistance to endocrine therapy in advanced breast cancer that is …

Purpose The antiepidermal growth factor receptor (EGFR) antibody cetuximab shows activity
in multiple epithelial tumor types; however, responses are seen in only a subset of patients …

Background Intravenous bolus fluorouracil plus leucovorin is the standard adjuvant
treatment for colon cancer. The oral fluoropyrimidine capecitabine is an established …